Estriol (medication)

This article is about estriol as a medication. For its role as a hormone, see Estriol.

Estriol (medication)

Clinical data
Pronunciation	/ˈɛstriɒl,-traɪɒl/ [1] ESS-TREE-ohl [1]
Trade names	Ovestin, others [2] [3]
Other names	Oestriol; E3; 16α-Hydroxyestradiol; Estra-1,3,5(10)-triene-3,16α,17β-triol
Routes of administration	By mouth, vaginal, intramuscular injection [4] [5] [6]
Drug class	Estrogen
ATC code	G03CA04 ( WHO ) G03CC06 ( WHO )
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	Oral: ~1–2% [4] [6] Vaginal: ~10–20% [5] [4] [6]
Protein binding	92%: [4] • Albumin: 91% [4] • SHBG Tooltip Sex hormone-binding globulin: 1% [4] • Free: 8% [4]
Metabolism	Liver, intestines (conjugation (glucuronidation, sulfation), oxidation, hydroxylation) [4]
Metabolites	• Estriol 16α-glucuronide [7] [5] • Estriol 3-glucuronide [7] [5] • Estriol 3-sulfate [7] [5] • Estriol 3-sulfate 16α-gluc. [7] [5] • 16α-Hydroxyestrone [4] [8] • Others (minor) [4]
Elimination half-life	Oral: 5–10 hours [9] [8] IM Tooltip Intramuscular injection: 1.5–5.3 hours (as E3) [5] IV Tooltip Intravenous injection: 20 minutes (as E3) [10] [11]
Excretion	Urine: >95% (as conjugates) [4] [5]
Identifiers
IUPAC name (8R,9S,13S,14S,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol
CAS Number	50-27-1  Y 1306-04-3 514-68-1 (succinate)
PubChem CID	5756
IUPHAR/BPS	2821
DrugBank	DB04573  Y
ChemSpider	5553  Y
UNII	FB33469R8E
KEGG	C05141  Y
ChEBI	CHEBI:27974  Y
ChEMBL	ChEMBL193482  Y
Chemical and physical data
Formula	C18H24O3
Molar mass	288.387 g·mol−1
3D model (JSmol)	Interactive image
Melting point	82 to 86 °C (180 to 187 °F) (experimental)
Solubility in water	0.119 mg/mL (20 °C)
SMILES Oc1cc3c(cc1)[C@H]2CC[C@@]4([C@@H](O)[C@H](O)C[C@H]4[C@@H]2CC3)C
InChI InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1 Y Key:PROQIPRRNZUXQM-ZXXIGWHRSA-N Y
(verify)

Estriol (E3), sold under the brand name Ovestin among others, is an estrogen medication and naturally occurring steroid hormone which is used in menopausal hormone therapy. ^{[12] [4] [6] [13]} It is also used in veterinary medicine as Incurin to treat urinary incontinence due to estrogen deficiency in dogs. ^{[14] [15] [16] [17]} The medication is taken by mouth in the form of tablets, as a cream that is applied to the skin, as a cream or pessary that is applied in the vagina, and by injection into muscle. ^{[4] [5] [6]}

Estriol is well-tolerated and produces relatively few adverse effects. ^{[12] [18]} Side effects may include breast tenderness, vaginal discomfort and discharge, and endometrial hyperplasia. ^{[12] [18]} Estriol is a naturally occurring and bioidentical estrogen, or an agonist of the estrogen receptor, the biological target of estrogens like endogenous estradiol. ^[4] It is an atypical and relatively weak estrogen, with much lower potency than estradiol. ^{[4] [6] [19]} When present continuously at adequate concentrations however, estriol produces full estrogenic effects similarly to estradiol. ^{[20] [21]}

Estriol was first discovered in 1930, ^{[22] [23]} and was introduced for medical use shortly thereafter. ^{[24] [25]} Estriol esters such as estriol succinate are also used. ^{[4] [18] [3]} Although it is less commonly employed than other estrogens like estradiol and conjugated estrogens, estriol is widely available for medical use in Europe and elsewhere throughout the world. ^{[4] [2] [3] [6]}

Medical uses

Estriol is used in menopausal hormone therapy to treat menopausal symptoms, such as hot flashes, vulvovaginal atrophy, and dyspareunia (difficult or painful sexual intercourse). ^{[12] [4] [13] [26] [18]} The benefits of estriol on bone mineral density and osteoporosis prevention have been inconsistent and are less clear. ^{[18] [12]} Estriol has been found to reduce the risk of urinary tract infections and other urogenital symptoms. ^{[4] [12]} A combination of estriol and lactobacilli as a dual estrogen and probiotic has been marketed for the treatment of vaginal atrophy and urinary tract infections. ^[27]

• v
• t
• e

Estrogen dosages for menopausal hormone therapy

Route/form	Estrogen	Low	Standard	High
Oral	Estradiol	0.5–1 mg/day	1–2 mg/day	2–4 mg/day
	Estradiol valerate	0.5–1 mg/day	1–2 mg/day	2–4 mg/day
	Estradiol acetate	0.45–0.9 mg/day	0.9–1.8 mg/day	1.8–3.6 mg/day
	Conjugated estrogens	0.3–0.45 mg/day	0.625 mg/day	0.9–1.25 mg/day
	Esterified estrogens	0.3–0.45 mg/day	0.625 mg/day	0.9–1.25 mg/day
	Estropipate	0.75 mg/day	1.5 mg/day	3 mg/day
	Estriol	1–2 mg/day	2–4 mg/day	4–8 mg/day
	Ethinylestradiol a	2.5–10 μg/day	5–20 μg/day	–
Nasal spray	Estradiol	150 μg/day	300 μg/day	600 μg/day
Transdermal patch	Estradiol	25 μg/dayb	50 μg/dayb	100 μg/dayb
Transdermal gel	Estradiol	0.5 mg/day	1–1.5 mg/day	2–3 mg/day
Vaginal	Estradiol	25 μg/day	–	–
	Estriol	30 μg/day	0.5 mg 2x/week	0.5 mg/day
IM Tooltip Intramuscular or SC injection	Estradiol valerate	–	–	4 mg 1x/4 weeks
	Estradiol cypionate	1 mg 1x/3–4 weeks	3 mg 1x/3–4 weeks	5 mg 1x/3–4 weeks
	Estradiol benzoate	0.5 mg 1x/week	1 mg 1x/week	1.5 mg 1x/week
SC implant	Estradiol	25 mg 1x/6 months	50 mg 1x/6 months	100 mg 1x/6 months
Footnotes:a = No longer used or recommended, due to health concerns. b = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. Note: Dosages are not necessarily equivalent. Sources: See template.

Available forms (except USA)

Estriol is available in oral tablet, vaginal cream, and vaginal suppository forms. ^[13] It is also available over-the-counter or from compounding pharmacies in the form of topical creams. ^[28] The medication is available both as estriol and in the form of estriol ester prodrugs such as estriol succinate, estriol acetate benzoate, and estriol tripropionate, as well as the polymeric ester prodrug polyestriol phosphate. ^{[4] [18] [29] [2] [3]}

Estriol was originally marketed in the 1930s in the form of oral capsules containing 0.06, 0.12, or 0.24 mg estriol under the brand names Theelol (Parke-Davis) and Estriol (Lilly, Abbott). ^{[30] [31] [32] [33] [34]} Subsequently, many decades later, oral tablets containing 0.35, 1, or 2 mg estriol were introduced under brand names such as Gynäsan, Hormomed, Ovestin, and Ovo-Vinces. ^[35]

Contraindications

See also: Estrogen (medication) § Contraindications, and Estradiol (medication) § Contraindications

General contraindications of estrogens include breast cancer, endometrial cancer, and others. ^[19] In animals, estriol is contraindicated during pregnancy and in ferrets. ^[17]

Side effects

Estriol is well-tolerated and produces relatively few adverse effects. ^{[12] [18]} Breast tenderness may sometimes occur as a side effect of estriol. ^[12] Local reactions with vaginal estriol such as discomfort (irritation, burning, itching) and discharge may occur. ^[12] Estriol may produce endometrial hyperplasia similarly to estradiol and other estrogens, and hence should be combined with a progestogen in women with intact uteruses to prevent this risk. ^{[36] [4]} However, it appears that typical clinical dosages of vaginal estriol are not associated with an important risk of endometrial proliferation or hyperplasia. ^{[12] [26]} As such, combination with a progestogen may not be needed in the case of vaginal estriol. ^{[12] [26]} Some studies suggest that this may also be true for oral estriol. ^[18] However, dosage and frequency of administration, as well as meal consumption, may be determining factors as to whether or not estriol produces endometrial proliferation. ^[4]

Overdose

See also: Estrogen (medication) § Overdose, and Estradiol (medication) § Overdose

Estrogens and other steroids are relatively safe in acute overdose.^{[ citation needed ]} Estriol has been assessed in single oral doses of up to 75 mg. ^{[37] [38]} General symptoms of estrogen overdose in humans may include nausea, vomiting, vaginal bleeding, and reversible feminization. ^{[39] [16]} While there are no known studies describing the acute toxicity of estrogen overdose in dogs, this species is known to be more sensitive to the toxic effects of estrogens than humans and other animals. ^[16] The most serious short-term adverse effect of estrogens in dogs is bone marrow suppression and consequent pancytopenia, which can be life-threatening. ^[16]

Interactions

See also: Estrogen (medication) § Interactions, and Estradiol (medication) § Interactions

Interactions with estriol might be expected to be similar to those of estradiol. ^[40] No interactions with estriol have been reported in animals. ^[17] However, it should not be used in combination with other drugs that suppress bone marrow production in dogs. ^[17]

Pharmacology

Pharmacodynamics

Estriol is an estrogen, or an agonist of the estrogen receptors (ERs), ERα and ERβ. ^{[4] [41] [42]} In terms of relative binding affinities (RBA) for the ERs compared to estradiol, it was found in one study to possess 11 to 14% of the RBA for the human ERα and 18 to 21% of the RBA for the human ERβ. ^[42] Its relative transactivational capacities at the ERs compared to estradiol were 11% at ERα and 17% at ERβ. ^[42] In addition to being a ligand of the classical nuclear ERs, estriol is an antagonist of the G protein-coupled estrogen receptor (GPER), a membrane estrogen receptor (mER), at high concentrations (~1,000–10,000 μM). ^{[43] [44] [41] [45]} This is in contrast to estradiol, which is an agonist of this receptor. ^{[44] [41] [45]} Like other estrogens, estriol does not importantly interact with other steroid hormone receptors. ^{[46] [47] [48] [49] [50]}

Estriol is a much less potent estrogen than is estradiol, and is somewhat weak and atypical in its properties. ^{[4] [42] [44] [19]} Given by subcutaneous injection in mice, estradiol is about 10-fold more potent than estrone and about 100-fold more potent than estriol. ^[51] With clinical use, estriol is said to be weakly estrogenic in certain tissues, such as the liver and endometrium, but produces pronounced and full estrogenic responses in the vaginal epithelium. ^[4] The medication has been found to reduce hot flashes, improve vaginal atrophy, reverse the postmenopausal decline in skin thickness and collagen content, suppress gonadotropin secretion, and produce proliferation of breast epithelium. ^[4] Conversely, estriol does not consistently affect bone resorption or fracture risk, does not seem to increase breast density, and, at oral doses of 2 to 4 mg/day, does not affect liver proteins, lipid metabolism, or hemostatic parameters. ^{[4] [18]} Additionally, vaginal estriol does not appear to produce endometrial proliferation or increase the risk of endometrial hyperplasia, and some studies have found this to be the case for oral estriol as well. ^{[4] [18] [52]} On the other hand, it appears that estriol may be able to stimulate the growth of active breast cancer. ^{[18] [12]} In rodents, estriol induces mammary gland development similar to that with estrone. ^[53] By the oral route in women, estriol has approximately 30% of the potency of estradiol in terms of hot flashes relief and suppression of follicle-stimulating hormone secretion, and about 20% of the potency of estradiol on stimulation of liver production of high-density lipoprotein (HDL) cholesterol. ^[4] A study of ovulation inhibition by estrogens in women found that prevention of ovulation occurred with 5 mg/day oral estriol in only 1 of 7 cycles. ^{[54] [55]} Due to its differing effects from those of estradiol, estriol may be considered a safer estrogen in certain regards. ^[12]

Nuclear retention of the receptor estrogen complex in the uterus with a single short-acting subcutaneous injection of 0.1 μg estradiol (E2), 1.0 μg estriol (E3), or a combination of 0.1 μg estradiol and 1.0 μg estriol in aqueous solution in rats. Estriol displaces estradiol from the estrogen receptors and, due to the shorter nuclear retention of estriol, it thereby antagonizes overall nuclear retention. No antagonism occurs when long-acting subcutaneous pellets of estriol are used instead.

The weak and atypical estrogenicity of estriol is thought to be related to its short duration in the body and hence the fact that it stays bound to the ER for a relatively short amount of time. ^{[4] [21]} Whereas estradiol remains bound to the ER for 6 to 24 hours with a single short-acting injection, estriol dissociates from the receptor much more rapidly and stays bound for only 1 to 6 hours. ^{[4] [21] [58] [59]} As a result, estriol can only induce estrogenic effects which require short-term interaction with the ERs. ^{[4] [21]} Induction of endometrial mitoses requires the ligand to remain bound for at least 9 to 12 hours, and this is thought to be responsible for the lack of endometrial proliferation with estriol in many studies. ^{[4] [21]} If estriol is delivered more continuously than a single administration per day however, for instance if it is given as a subcutaneous pellet, as a depot injection, or in multiple doses two or three times per day, this results in more sustained exposure to estriol and full estrogenic responses equivalent to those of estradiol occur. ^{[4] [21] [12]} For these reasons, estriol has been described as a "short-acting" estrogen and it has been said that descriptors like "weak" and "impeded" are inaccurate. ^[21] Consumption of food after oral administration of estriol also results in more prolonged exposure to estriol, due to enterohepatic recycling and resurgences in estriol levels. ^[4] As such, if avoidance of endometrial hyperplasia or other full estrogenic effects is intended, it may be preferable to take estriol in a single dose, as low as possible, once per day at night before bedtime. ^{[4] [52]}

Although estriol is an estrogen, it has also been reported to have mixed agonist–antagonist or partial agonist activity at the ERs. ^{[4] [21] [19]} On its own, it is said to be weakly estrogenic, but in the presence of estradiol, it has been found to be antiestrogenic. ^{[4] [44]} However, this is again due to the fact that estriol is a "short-acting" estrogen. ^[21] If estriol is present continuously with estradiol, it shows no antagonism of estradiol. ^[21] The co-administration of estriol with estradiol has been found not to influence the effects of the latter in women, including neither enhancing nor antagonizing the effects of estradiol. ^{[52] [60]}

• v
• t
• e

Affinities of estrogen receptor ligands for the ERα and ERβ

Ligand	Other names	Relative binding affinities (RBA, %)a		Absolute binding affinities (Ki, nM)a		Action
		ERα	ERβ	ERα	ERβ
Estradiol	E2; 17β-Estradiol	100	100	0.115 (0.04–0.24)	0.15 (0.10–2.08)	Estrogen
Estrone	E1; 17-Ketoestradiol	16.39 (0.7–60)	6.5 (1.36–52)	0.445 (0.3–1.01)	1.75 (0.35–9.24)	Estrogen
Estriol	E3; 16α-OH-17β-E2	12.65 (4.03–56)	26 (14.0–44.6)	0.45 (0.35–1.4)	0.7 (0.63–0.7)	Estrogen
Estetrol	E4; 15α,16α-Di-OH-17β-E2	4.0	3.0	4.9	19	Estrogen
Alfatradiol	17α-Estradiol	20.5 (7–80.1)	8.195 (2–42)	0.2–0.52	0.43–1.2	Metabolite
16-Epiestriol	16β-Hydroxy-17β-estradiol	7.795 (4.94–63)	50	?	?	Metabolite
17-Epiestriol	16α-Hydroxy-17α-estradiol	55.45 (29–103)	79–80	?	?	Metabolite
16,17-Epiestriol	16β-Hydroxy-17α-estradiol	1.0	13	?	?	Metabolite
2-Hydroxyestradiol	2-OH-E2	22 (7–81)	11–35	2.5	1.3	Metabolite
2-Methoxyestradiol	2-MeO-E2	0.0027–2.0	1.0	?	?	Metabolite
4-Hydroxyestradiol	4-OH-E2	13 (8–70)	7–56	1.0	1.9	Metabolite
4-Methoxyestradiol	4-MeO-E2	2.0	1.0	?	?	Metabolite
2-Hydroxyestrone	2-OH-E1	2.0–4.0	0.2–0.4	?	?	Metabolite
2-Methoxyestrone	2-MeO-E1	<0.001–<1	<1	?	?	Metabolite
4-Hydroxyestrone	4-OH-E1	1.0–2.0	1.0	?	?	Metabolite
4-Methoxyestrone	4-MeO-E1	<1	<1	?	?	Metabolite
16α-Hydroxyestrone	16α-OH-E1; 17-Ketoestriol	2.0–6.5	35	?	?	Metabolite
2-Hydroxyestriol	2-OH-E3	2.0	1.0	?	?	Metabolite
4-Methoxyestriol	4-MeO-E3	1.0	1.0	?	?	Metabolite
Estradiol sulfate	E2S; Estradiol 3-sulfate	<1	<1	?	?	Metabolite
Estradiol disulfate	Estradiol 3,17β-disulfate	0.0004	?	?	?	Metabolite
Estradiol 3-glucuronide	E2-3G	0.0079	?	?	?	Metabolite
Estradiol 17β-glucuronide	E2-17G	0.0015	?	?	?	Metabolite
Estradiol 3-gluc. 17β-sulfate	E2-3G-17S	0.0001	?	?	?	Metabolite
Estrone sulfate	E1S; Estrone 3-sulfate	<1	<1	>10	>10	Metabolite
Estradiol benzoate	EB; Estradiol 3-benzoate	10	?	?	?	Estrogen
Estradiol 17β-benzoate	E2-17B	11.3	32.6	?	?	Estrogen
Estrone methyl ether	Estrone 3-methyl ether	0.145	?	?	?	Estrogen
ent-Estradiol	1-Estradiol	1.31–12.34	9.44–80.07	?	?	Estrogen
Equilin	7-Dehydroestrone	13 (4.0–28.9)	13.0–49	0.79	0.36	Estrogen
Equilenin	6,8-Didehydroestrone	2.0–15	7.0–20	0.64	0.62	Estrogen
17β-Dihydroequilin	7-Dehydro-17β-estradiol	7.9–113	7.9–108	0.09	0.17	Estrogen
17α-Dihydroequilin	7-Dehydro-17α-estradiol	18.6 (18–41)	14–32	0.24	0.57	Estrogen
17β-Dihydroequilenin	6,8-Didehydro-17β-estradiol	35–68	90–100	0.15	0.20	Estrogen
17α-Dihydroequilenin	6,8-Didehydro-17α-estradiol	20	49	0.50	0.37	Estrogen
Δ8-Estradiol	8,9-Dehydro-17β-estradiol	68	72	0.15	0.25	Estrogen
Δ8-Estrone	8,9-Dehydroestrone	19	32	0.52	0.57	Estrogen
Ethinylestradiol	EE; 17α-Ethynyl-17β-E2	120.9 (68.8–480)	44.4 (2.0–144)	0.02–0.05	0.29–0.81	Estrogen
Mestranol	EE 3-methyl ether	?	2.5	?	?	Estrogen
Moxestrol	RU-2858; 11β-Methoxy-EE	35–43	5–20	0.5	2.6	Estrogen
Methylestradiol	17α-Methyl-17β-estradiol	70	44	?	?	Estrogen
Diethylstilbestrol	DES; Stilbestrol	129.5 (89.1–468)	219.63 (61.2–295)	0.04	0.05	Estrogen
Hexestrol	Dihydrodiethylstilbestrol	153.6 (31–302)	60–234	0.06	0.06	Estrogen
Dienestrol	Dehydrostilbestrol	37 (20.4–223)	56–404	0.05	0.03	Estrogen
Benzestrol (B2)	–	114	?	?	?	Estrogen
Chlorotrianisene	TACE	1.74	?	15.30	?	Estrogen
Triphenylethylene	TPE	0.074	?	?	?	Estrogen
Triphenylbromoethylene	TPBE	2.69	?	?	?	Estrogen
Tamoxifen	ICI-46,474	3 (0.1–47)	3.33 (0.28–6)	3.4–9.69	2.5	SERM
Afimoxifene	4-Hydroxytamoxifen; 4-OHT	100.1 (1.7–257)	10 (0.98–339)	2.3 (0.1–3.61)	0.04–4.8	SERM
Toremifene	4-Chlorotamoxifen; 4-CT	?	?	7.14–20.3	15.4	SERM
Clomifene	MRL-41	25 (19.2–37.2)	12	0.9	1.2	SERM
Cyclofenil	F-6066; Sexovid	151–152	243	?	?	SERM
Nafoxidine	U-11,000A	30.9–44	16	0.3	0.8	SERM
Raloxifene	–	41.2 (7.8–69)	5.34 (0.54–16)	0.188–0.52	20.2	SERM
Arzoxifene	LY-353,381	?	?	0.179	?	SERM
Lasofoxifene	CP-336,156	10.2–166	19.0	0.229	?	SERM
Ormeloxifene	Centchroman	?	?	0.313	?	SERM
Levormeloxifene	6720-CDRI; NNC-460,020	1.55	1.88	?	?	SERM
Ospemifene	Deaminohydroxytoremifene	0.82–2.63	0.59–1.22	?	?	SERM
Bazedoxifene	–	?	?	0.053	?	SERM
Etacstil	GW-5638	4.30	11.5	?	?	SERM
ICI-164,384	–	63.5 (3.70–97.7)	166	0.2	0.08	Antiestrogen
Fulvestrant	ICI-182,780	43.5 (9.4–325)	21.65 (2.05–40.5)	0.42	1.3	Antiestrogen
Propylpyrazoletriol	PPT	49 (10.0–89.1)	0.12	0.40	92.8	ERα agonist
16α-LE2	16α-Lactone-17β-estradiol	14.6–57	0.089	0.27	131	ERα agonist
16α-Iodo-E2	16α-Iodo-17β-estradiol	30.2	2.30	?	?	ERα agonist
Methylpiperidinopyrazole	MPP	11	0.05	?	?	ERα antagonist
Diarylpropionitrile	DPN	0.12–0.25	6.6–18	32.4	1.7	ERβ agonist
8β-VE2	8β-Vinyl-17β-estradiol	0.35	22.0–83	12.9	0.50	ERβ agonist
Prinaberel	ERB-041; WAY-202,041	0.27	67–72	?	?	ERβ agonist
ERB-196	WAY-202,196	?	180	?	?	ERβ agonist
Erteberel	SERBA-1; LY-500,307	?	?	2.68	0.19	ERβ agonist
SERBA-2	–	?	?	14.5	1.54	ERβ agonist
Coumestrol	–	9.225 (0.0117–94)	64.125 (0.41–185)	0.14–80.0	0.07–27.0	Xenoestrogen
Genistein	–	0.445 (0.0012–16)	33.42 (0.86–87)	2.6–126	0.3–12.8	Xenoestrogen
Equol	–	0.2–0.287	0.85 (0.10–2.85)	?	?	Xenoestrogen
Daidzein	–	0.07 (0.0018–9.3)	0.7865 (0.04–17.1)	2.0	85.3	Xenoestrogen
Biochanin A	–	0.04 (0.022–0.15)	0.6225 (0.010–1.2)	174	8.9	Xenoestrogen
Kaempferol	–	0.07 (0.029–0.10)	2.2 (0.002–3.00)	?	?	Xenoestrogen
Naringenin	–	0.0054 (<0.001–0.01)	0.15 (0.11–0.33)	?	?	Xenoestrogen
8-Prenylnaringenin	8-PN	4.4	?	?	?	Xenoestrogen
Quercetin	–	<0.001–0.01	0.002–0.040	?	?	Xenoestrogen
Ipriflavone	–	<0.01	<0.01	?	?	Xenoestrogen
Miroestrol	–	0.39	?	?	?	Xenoestrogen
Deoxymiroestrol	–	2.0	?	?	?	Xenoestrogen
β-Sitosterol	–	<0.001–0.0875	<0.001–0.016	?	?	Xenoestrogen
Resveratrol	–	<0.001–0.0032	?	?	?	Xenoestrogen
α-Zearalenol	–	48 (13–52.5)	?	?	?	Xenoestrogen
β-Zearalenol	–	0.6 (0.032–13)	?	?	?	Xenoestrogen
Zeranol	α-Zearalanol	48–111	?	?	?	Xenoestrogen
Taleranol	β-Zearalanol	16 (13–17.8)	14	0.8	0.9	Xenoestrogen
Zearalenone	ZEN	7.68 (2.04–28)	9.45 (2.43–31.5)	?	?	Xenoestrogen
Zearalanone	ZAN	0.51	?	?	?	Xenoestrogen
Bisphenol A	BPA	0.0315 (0.008–1.0)	0.135 (0.002–4.23)	195	35	Xenoestrogen
Endosulfan	EDS	<0.001–<0.01	<0.01	?	?	Xenoestrogen
Kepone	Chlordecone	0.0069–0.2	?	?	?	Xenoestrogen
o,p'-DDT	–	0.0073–0.4	?	?	?	Xenoestrogen
p,p'-DDT	–	0.03	?	?	?	Xenoestrogen
Methoxychlor	p,p'-Dimethoxy-DDT	0.01 (<0.001–0.02)	0.01–0.13	?	?	Xenoestrogen
HPTE	Hydroxychlor; p,p'-OH-DDT	1.2–1.7	?	?	?	Xenoestrogen
Testosterone	T; 4-Androstenolone	<0.0001–<0.01	<0.002–0.040	>5000	>5000	Androgen
Dihydrotestosterone	DHT; 5α-Androstanolone	0.01 (<0.001–0.05)	0.0059–0.17	221–>5000	73–1688	Androgen
Nandrolone	19-Nortestosterone; 19-NT	0.01	0.23	765	53	Androgen
Dehydroepiandrosterone	DHEA; Prasterone	0.038 (<0.001–0.04)	0.019–0.07	245–1053	163–515	Androgen
5-Androstenediol	A5; Androstenediol	6	17	3.6	0.9	Androgen
4-Androstenediol	–	0.5	0.6	23	19	Androgen
4-Androstenedione	A4; Androstenedione	<0.01	<0.01	>10000	>10000	Androgen
3α-Androstanediol	3α-Adiol	0.07	0.3	260	48	Androgen
3β-Androstanediol	3β-Adiol	3	7	6	2	Androgen
Androstanedione	5α-Androstanedione	<0.01	<0.01	>10000	>10000	Androgen
Etiocholanedione	5β-Androstanedione	<0.01	<0.01	>10000	>10000	Androgen
Methyltestosterone	17α-Methyltestosterone	<0.0001	?	?	?	Androgen
Ethinyl-3α-androstanediol	17α-Ethynyl-3α-adiol	4.0	<0.07	?	?	Estrogen
Ethinyl-3β-androstanediol	17α-Ethynyl-3β-adiol	50	5.6	?	?	Estrogen
Progesterone	P4; 4-Pregnenedione	<0.001–0.6	<0.001–0.010	?	?	Progestogen
Norethisterone	NET; 17α-Ethynyl-19-NT	0.085 (0.0015–<0.1)	0.1 (0.01–0.3)	152	1084	Progestogen
Norethynodrel	5(10)-Norethisterone	0.5 (0.3–0.7)	<0.1–0.22	14	53	Progestogen
Tibolone	7α-Methylnorethynodrel	0.5 (0.45–2.0)	0.2–0.076	?	?	Progestogen
Δ4-Tibolone	7α-Methylnorethisterone	0.069–<0.1	0.027–<0.1	?	?	Progestogen
3α-Hydroxytibolone	–	2.5 (1.06–5.0)	0.6–0.8	?	?	Progestogen
3β-Hydroxytibolone	–	1.6 (0.75–1.9)	0.070–0.1	?	?	Progestogen
Footnotes:a = (1) Binding affinity values are of the format "median (range)" (# (#–#)), "range" (#–#), or "value" (#) depending on the values available. The full sets of values within the ranges can be found in the Wiki code. (2) Binding affinities were determined via displacement studies in a variety of in-vitro systems with labeled estradiol and human ERα and ERβ proteins (except the ERβ values from Kuiper et al. (1997), which are rat ERβ). Sources: See template page.

• v
• t
• e

Relative affinities of estrogens for steroid hormone receptors and blood proteins

Estrogen	Relative binding affinities (%)
	ER Tooltip Estrogen receptor	AR Tooltip Androgen receptor	PR Tooltip Progesterone receptor	GR Tooltip Glucocorticoid receptor	MR Tooltip Mineralocorticoid receptor	SHBG Tooltip Sex hormone-binding globulin	CBG Tooltip Corticosteroid binding globulin
Estradiol	100	7.9	2.6	0.6	0.13	8.7–12	<0.1
Estradiol benzoate	?	?	?	?	?	<0.1–0.16	<0.1
Estradiol valerate	2	?	?	?	?	?	?
Estrone	11–35	<1	<1	<1	<1	2.7	<0.1
Estrone sulfate	2	2	?	?	?	?	?
Estriol	10–15	<1	<1	<1	<1	<0.1	<0.1
Equilin	40	?	?	?	?	?	0
Alfatradiol	15	<1	<1	<1	<1	?	?
Epiestriol	20	<1	<1	<1	<1	?	?
Ethinylestradiol	100–112	1–3	15–25	1–3	<1	0.18	<0.1
Mestranol	1	?	?	?	?	<0.1	<0.1
Methylestradiol	67	1–3	3–25	1–3	<1	?	?
Moxestrol	12	<0.1	0.8	3.2	<0.1	<0.2	<0.1
Diethylstilbestrol	?	?	?	?	?	<0.1	<0.1
Notes: Reference ligands (100%) were progesterone for the PR Tooltip progesterone receptor, testosterone for the AR Tooltip androgen receptor, estradiol for the ER Tooltip estrogen receptor, dexamethasone for the GR Tooltip glucocorticoid receptor, aldosterone for the MR Tooltip mineralocorticoid receptor, dihydrotestosterone for SHBG Tooltip sex hormone-binding globulin, and cortisol for CBG Tooltip Corticosteroid-binding globulin. Sources: See template.

• v
• t
• e

Selected biological properties of endogenous estrogens in rats

Estrogen	ER Tooltip Estrogen receptor RBA Tooltip relative binding affinity (%)	Uterine weight (%)	Uterotrophy	LH Tooltip Luteinizing hormone levels (%)	SHBG Tooltip Sex hormone-binding globulin RBA Tooltip relative binding affinity (%)
Control	–	100	–	100	–
Estradiol (E2)	100	506 ± 20	+++	12–19	100
Estrone (E1)	11 ± 8	490 ± 22	+++	?	20
Estriol (E3)	10 ± 4	468 ± 30	+++	8–18	3
Estetrol (E4)	0.5 ± 0.2	?	Inactive	?	1
17α-Estradiol	4.2 ± 0.8	?	?	?	?
2-Hydroxyestradiol	24 ± 7	285 ± 8	+b	31–61	28
2-Methoxyestradiol	0.05 ± 0.04	101	Inactive	?	130
4-Hydroxyestradiol	45 ± 12	?	?	?	?
4-Methoxyestradiol	1.3 ± 0.2	260	++	?	9
4-Fluoroestradiol a	180 ± 43	?	+++	?	?
2-Hydroxyestrone	1.9 ± 0.8	130 ± 9	Inactive	110–142	8
2-Methoxyestrone	0.01 ± 0.00	103 ± 7	Inactive	95–100	120
4-Hydroxyestrone	11 ± 4	351	++	21–50	35
4-Methoxyestrone	0.13 ± 0.04	338	++	65–92	12
16α-Hydroxyestrone	2.8 ± 1.0	552 ± 42	+++	7–24	<0.5
2-Hydroxyestriol	0.9 ± 0.3	302	+b	?	?
2-Methoxyestriol	0.01 ± 0.00	?	Inactive	?	4
Notes: Values are mean ± SD or range. ERRBA = Relative binding affinity to estrogen receptors of rat uterine cytosol. Uterine weight = Percentage change in uterine wet weight of ovariectomized rats after 72 hours with continuous administration of 1 μg/hour via subcutaneously implanted osmotic pumps. LH levels = Luteinizing hormone levels relative to baseline of ovariectomized rats after 24 to 72 hours of continuous administration via subcutaneous implant. Footnotes:a = Synthetic (i.e., not endogenous). b = Atypical uterotrophic effect which plateaus within 48 hours (estradiol's uterotrophy continues linearly up to 72 hours). Sources: See template.

• v
• t
• e

Relative oral potencies of estrogens

Estrogen	HF Tooltip Hot flashes	VE Tooltip Vaginal epithelium	UCa Tooltip Urinary calcium	FSH Tooltip Follicle-stimulating hormone	LH Tooltip Luteinizing hormone	HDL Tooltip High-density lipoprotein-C Tooltip Cholesterol	SHBG Tooltip Sex hormone-binding globulin	CBG Tooltip Corticosteroid-binding globulin	AGT Tooltip Angiotensinogen	Liver
Estradiol	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Estrone	?	?	?	0.3	0.3	?	?	?	?	?
Estriol	0.3	0.3	0.1	0.3	0.3	0.2	?	?	?	0.67
Estrone sulfate	?	0.9	0.9	0.8–0.9	0.9	0.5	0.9	0.5–0.7	1.4–1.5	0.56–1.7
Conjugated estrogens	1.2	1.5	2.0	1.1–1.3	1.0	1.5	3.0–3.2	1.3–1.5	5.0	1.3–4.5
Equilin sulfate	?	?	1.0	?	?	6.0	7.5	6.0	7.5	?
Ethinylestradiol	120	150	400	60–150	100	400	500–600	500–600	350	2.9–5.0
Diethylstilbestrol	?	?	?	2.9–3.4	?	?	26–28	25–37	20	5.7–7.5
Sources and footnotes Notes: Values are ratios, with estradiol as standard (i.e., 1.0). Abbreviations:HF = Clinical relief of hot flashes. VE = Increased proliferation of vaginal epithelium. UCa = Decrease in UCa Tooltip urinary calcium. FSH = Suppression of FSH Tooltip follicle-stimulating hormone levels. LH = Suppression of LH Tooltip luteinizing hormone levels. HDL-C, SHBG, CBG, and AGT = Increase in the serum levels of these liver proteins. Liver = Ratio of liver estrogenic effects to general/systemic estrogenic effects (hot flashes/gonadotropins). Sources: See template.

• v
• t
• e

Potencies of oral estrogens ^{[data sources 1]}

Compound	Dosage for specific uses (mg usually) [lower-alpha 1]
	ETD [lower-alpha 2]	EPD [lower-alpha 2]	MSD [lower-alpha 2]	MSD [lower-alpha 3]	OID [lower-alpha 3]	TSD [lower-alpha 3]
Estradiol (non-micronized)	30	≥120–300	120	6	-	-
Estradiol (micronized)	6–12	60–80	14–42	1–2	>5	>8
Estradiol valerate	6–12	60–80	14–42	1–2	-	>8
Estradiol benzoate	-	60–140	-	-	-	-
Estriol	≥20	120–150 [lower-alpha 4]	28–126	1–6	>5	-
Estriol succinate	-	140–150 [lower-alpha 4]	28–126	2–6	-	-
Estrone sulfate	12	60	42	2	-	-
Conjugated estrogens	5–12	60–80	8.4–25	0.625–1.25	>3.75	7.5
Ethinylestradiol	200 μg	1–2	280 μg	20–40 μg	100 μg	100 μg
Mestranol	300 μg	1.5–3.0	300–600 μg	25–30 μg	>80 μg	-
Quinestrol	300 μg	2–4	500 μg	25–50 μg	-	-
Methylestradiol	-	2	-	-	-	-
Diethylstilbestrol	2.5	20–30	11	0.5–2.0	>5	3
DES dipropionate	-	15–30	-	-	-	-
Dienestrol	5	30–40	42	0.5–4.0	-	-
Dienestrol diacetate	3–5	30–60	-	-	-	-
Hexestrol	-	70–110	-	-	-	-
Chlorotrianisene	-	>100	-	-	>48	-
Methallenestril	-	400	-	-	-	-
Sources and footnotes: [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] Dosages are given in milligrams unless otherwise noted. Dosed every 2 to 3 weeks Dosed daily In divided doses, 3x/day; irregular and atypical proliferation.

• v
• t
• e

Potencies and durations of natural estrogens by intramuscular injection

Estrogen	Form	Dose (mg)		Duration by dose (mg)
		EPD	CICD
Estradiol	Aq. soln.	?	–	<1 d
	Oil soln.	40–60	–	1–2 ≈ 1–2 d
	Aq. susp.	?	3.5	0.5–2 ≈ 2–7 d; 3.5 ≈ >5 d
	Microsph.	?	–	1 ≈ 30 d
Estradiol benzoate	Oil soln.	25–35	–	1.66 ≈ 2–3 d; 5 ≈ 3–6 d
	Aq. susp.	20	–	10 ≈ 16–21 d
	Emulsion	?	–	10 ≈ 14–21 d
Estradiol dipropionate	Oil soln.	25–30	–	5 ≈ 5–8 d
Estradiol valerate	Oil soln.	20–30	5	5 ≈ 7–8 d; 10 ≈ 10–14 d; 40 ≈ 14–21 d; 100 ≈ 21–28 d
Estradiol benz. butyrate	Oil soln.	?	10	10 ≈ 21 d
Estradiol cypionate	Oil soln.	20–30	–	5 ≈ 11–14 d
	Aq. susp.	?	5	5 ≈ 14–24 d
Estradiol enanthate	Oil soln.	?	5–10	10 ≈ 20–30 d
Estradiol dienanthate	Oil soln.	?	–	7.5 ≈ >40 d
Estradiol undecylate	Oil soln.	?	–	10–20 ≈ 40–60 d; 25–50 ≈ 60–120 d
Polyestradiol phosphate	Aq. soln.	40–60	–	40 ≈ 30 d; 80 ≈ 60 d; 160 ≈ 120 d
Estrone	Oil soln.	?	–	1–2 ≈ 2–3 d
	Aq. susp.	?	–	0.1–2 ≈ 2–7 d
Estriol	Oil soln.	?	–	1–2 ≈ 1–4 d
Polyestriol phosphate	Aq. soln.	?	–	50 ≈ 30 d; 80 ≈ 60 d
Notes and sources Notes: All aqueous suspensions are of microcrystalline particle size. Estradiol production during the menstrual cycle is 30–640 µg/d (6.4–8.6 mg total per month or cycle). The vaginal epithelium maturation dosage of estradiol benzoate or estradiol valerate has been reported as 5 to 7 mg/week. An effective ovulation-inhibiting dose of estradiol undecylate is 20–30 mg/month. Sources: See template.

• v
• t
• e

Classification of estrogens and antiestrogens by receptor–estrogen complex retention

Class	Examples	RE complex retention	Pharmacodynamic profile	Uterine effects
Short-acting (a.k.a. "weak" or "impeded")	Estriol • 16-Epiestriol • 17α-Estradiol • ent-Estradiol • 16-Ketoestradiol • Dimethylstilbestrol • meso-Butestrol	Short (1–4 hours)	Single or once-daily injections: partial agonist or antagonist	Early responsesa
			Implant or multiple injections per day: full agonist	Early and late responsesb
Long-acting	A. Estradiol • Estrone • Ethinylestradiol • Diethylstilbestrol • Hexestrol	Intermediate (6–24 hours)	Single or once-daily injections: full agonist	Early and late responses
	B. Clomifene • Nafoxidine • Nitromifene • Tamoxifen	Long (>24–48 hours)	Single injection: agonist Repeated injections: antagonist	Early and late responses
Footnotes:a = Early responses occur after 0–6 hours and include water imbibition, hyperemia, amino acid and nucleotide uptake, activation of RNA polymerases I and II, and stimulation of induced protein, among others. b = Late responses occur after 6–48 hours and include cellular hypertrophy and hyperplasia and sustained RNA polymerase I and II activity, among others. Sources: [80] [81] [82] [83] [84] [85] [86]

Pharmacokinetics

Estriol (E3) levels after a single dose during continuous daily administration of 8 mg oral estriol (with or without a meal at 4 hours) or 0.5 mg vaginal estriol. Note the second peak with oral estriol caused by consumption of a meal at 4 hours, which is due to enterohepatic recycling of the compound and a consequent resurgence in levels.

Absorption

Estriol has significant bioavailability, but its potency is limited by rapid metabolism and excretion and its relatively weak estrogenic activity. ^{[6] [18]} With oral administration, during first-pass metabolism, a considerable portion of estriol is conjugated via sulfation into estriol sulfate and rapidly excreted. ^{[6] [4] [52]} Only about 10 to 20% of a dose of estriol remains in the circulation, and of this, only about 1 to 2% is present in its active, unconjugated form. ^{[4] [6] [52]} Peak levels of estriol occur about 1 to 3 hours after an oral dose. ^{[4] [5]} Similarly to the case of progesterone, taking oral estriol with food greatly enhances its absorption. ^[6] In addition, due to enterohepatic recycling, consuming a meal 4 hours after taking oral estriol can produce a second peak in estriol levels. ^{[4] [5]} Dosages of oral estriol of 4 to 10 mg have been found to result in a fairly large range of maximal estriol levels of 80 to 340 pg/mL. ^[5] After a single oral dose of 8 mg estriol in postmenopausal women, maximal levels of 65 pg/mL estriol and 60 ng/mL estriol conjugates were produced within an hour. ^[4] With continued daily administration, this increased to peak levels of 130 pg/mL estriol, whereas maximal levels of estriol conjugates remained at 60 ng/mL. ^[4] Levels of estriol rapidly decreased to low levels following occurrence of peak levels. ^[4] Consumption of a meal 4 hours after taking an oral dose of 8 mg estriol during continuous daily administration resulted in a second estriol peak 2 hours later of 120 pg/mL, with estriol levels declining slowly thereafter to about 25 pg/mL after 24 hours. ^[4]

The bioavailability of estriol is markedly increased with vaginal administration compared to oral administration. ^[6] The relative bioavailability of oral estriol was found to be about 10% of that of vaginal estriol. ^[5] In accordance, a single dose of 8 mg oral estriol and of 0.5 mg vaginal estriol have been found to produce similar circulating concentrations of estriol. ^[4] It has been said that 0.5 to 1 mg vaginal estriol may be equivalent in clinical effect to 8 to 12 mg oral estriol. ^[18] The high bioavailability of vaginal estriol is due to rapid absorption and low metabolism in atrophic vaginal mucosa. ^[4] Vaginal estriol at typical clinical dosages results both in high local concentrations of estriol in the vagina and in systemic action. ^[4] Vaginal administration of low doses of 30 µg estriol and of higher doses of 0.5 and 1 mg estriol have been found to produce equivalent local effects in the vagina and improvement of vaginal symptoms, suggesting that a saturation of estrogenic effect of vaginal estriol has been reached in the vagina by a dose of only 30 µg estriol. ^[4] In contrast to higher doses of vaginal estriol however, 30 µg/day estriol is not associated with systemic effects. ^[4] Similarly, the use of 0.5 mg vaginal estriol twice a week instead of daily has been said to largely attenuate the systemic effects of estriol. ^[4] Whereas oral estriol results in high levels of estriol conjugates which greatly exceed those of unconjugated estriol, vaginal estriol has been found to produce levels of unconjugated estriol and estriol conjugates that are similar. ^[4]

The absorption of estrogens by the skin is described as low for estriol, moderate for estradiol, and high for estrone. ^[4] This is related to the number of hydroxyl groups in the molecules; the more hydroxyl groups, the lower the skin permeability. ^[4] This may account for the relative lack of use of transdermal or topical estriol. ^[6]

Rectal administration of estriol has been assessed in one study. ^[87] Administration of a rectal suppository containing 100 mg estriol resulted in estriol levels in pregnant women at term increasing by about 53%. ^[87] Estriol levels at term are normally between 5,000 and 20,000 pg/mL, which suggests that estriol levels may have increased following the suppository by about 5,000 to 10,000 pg/mL (precise levels were not provided). ^{[88] [89] [90]}

Estriol succinate is an ester prodrug of estriol which is used medically via oral and vaginal routes similarly. ^[4] In estriol succinate, two of the hydroxyl groups of estriol, those at the C16α and C17β positions, are esterified with succinic acid. ^[4] As such, when adjusted for differences in molecular weight, a dose of 2 mg estriol succinate is equivalent to 1.18 mg unconjugated estriol. ^[4] Unlike other estrogen esters, such as estradiol valerate, estriol succinate is hydrolyzed almost not at all in the intestinal mucosa when taken orally, and in relation to this, is absorbed more slowly than is estriol. ^[4] Consequently, oral estriol succinate is a longer-acting form of estriol than oral estriol. ^[20] Instead of in the gastrointestinal tract, oral estriol succinate is cleaved into estriol mainly in the liver. ^[4] After a single 8 mg oral dose of estriol succinate, maximum levels of circulating estriol of 40 pg/mL are attained within 12 hours, and this increases up to 80 pg/mL with continued daily administration. ^[4]

Distribution

Similarly to estradiol, but unlike estrone, estriol is accumulated in target tissues. ^{[4] [91]} The plasma protein binding of estriol is approximately 92%, with about 91% bound to albumin, 1% bound to sex hormone-binding globulin (SHBG), and 8% free or unbound. ^[4] Estriol has very low affinity for SHBG, with only about 0.3% of the affinity of testosterone for this protein (or about 0.6% of that of estradiol). ^{[4] [92] [93]} Relative to estradiol, which is about 98% plasma protein-bound, a significantly greater fraction of estriol is unbound in the circulation and hence available for biological activity (2% relative to 8%, respectively). ^{[93] [4] [18]} This appears to account for the greater than expected biological activity of estriol relative to estradiol when considering its affinities for the estrogen receptors. ^[94]

Metabolism

Estriol is metabolized extensively via conjugation, including glucuronidation and sulfation. ^{[4] [6] [5] [7]} Glucuronidation of estriol takes place mainly in the intestinal mucosa, while sulfation occurs in the liver. ^[4] More minor amounts of estriol can be oxidized and hydroxylated at various positions. ^[4] One such reaction is transformation into 16α-hydroxyestrone. ^[4] Estriol is an end-product of phase I estrogen metabolism and cannot be converted into estradiol or estrone. ^{[4] [52]} The main metabolites of estriol are estrogen conjugates, including estriol sulfates, estriol glucuronides, and mixed estriol sulfate/glucuronide conjugates. ^[4] 16α-Hydroxyestrone is known to occur as a metabolite of estriol as well. ^{[95] [96] [91]}

The biological half-life of oral estriol has been reported to be in the range of 5 to 10 hours. ^{[9] [8] [52]} The elimination half-life of estriol following an intramuscular injection of 1 mg estriol has been found to be 1.5 to 5.3 hours. ^[5] The blood half-life of unconjugated estriol has been reported to be 20 minutes. ^{[10] [11]} The metabolic clearance rate of estriol is approximately 1,110 L/day/m², which is about twice that of estradiol. ^[4] Hence, estriol is eliminated from the body more rapidly than is estradiol. ^[4] Enterohepatic recycling may extend the duration of oral estriol. ^[18]

A single 1 to 2 mg dose of estriol in oil solution by intramuscular injection has a duration of about 3 or 4 days. ^[97] Estriol esters such as estriol dipropionate and estriol dihexanoate, when administered via intramuscular injection in an oil solution, have been found to maintain elevated levels of estriol for much longer amounts of time than oral or vaginal estriol, in the range of days to months. ^[5] These two estriol esters have not been marketed, but estriol acetate benzoate and estriol tripropionate are medically used estriol esters which are given via depot intramuscular injection and are long-acting similarly. ^[29] Polyestriol phosphate is an ester of estriol in the form of a polymer, and has a very long duration of action. ^{[98] [51]}

Excretion

Estriol is excreted more than 95% in urine. ^[4] This is due to the fact that estriol conjugates in the colon are completely hydrolyzed via bacterial enzymes and in turn estriol in this part of the body is reabsorbed into the body. ^[4] The main urinary metabolites of exogenous estriol administered via intravenous injection in baboons have been found to be estriol 16α-glucuronide (65.8%), estriol 3-glucuronide (14.2%), estriol 3-sulfate (13.4%), and estriol 3-sulfate 16α-glucuronide (5.1%). ^{[5] [7]} The metabolism and excretion of estriol in these animals closely resembled that which has been observed in humans. ^[7]

Chemistry

v t e Structures of major endogenous estrogens Estrone (E1) Estradiol (E2) Estriol (E3) Estetrol (E4) Note the hydroxyl (–OH) groups: estrone (E1) has one, estradiol (E2) has two, estriol (E3) has three, and estetrol (E4) has four.

Estriol, also known as 16α-hydroxyestradiol or as estra-1,3,5(10)-triene-3,16α,17β-triol, is a naturally occurring estrane steroid with double bonds between the C1 and C2, C3 and C4, and C5 and C10 positions and hydroxyl groups at the C3, C16α, and C17β positions. ^{[29] [2]} The name estriol and the abbreviation E3 were derived from the chemical terms estrin (estra-1,3,5(10)-triene) and triol (three hydroxyl groups). ^[99]

Analogues

See also: List of estrogens § Estriol derivatives, and List of estrogen esters § Estriol esters

A variety of analogues of estriol are known, including both naturally occurring isomers and synthetic substituted derivatives and esters. ^{[29] [2]} 16β-Epiestriol (epiestriol), 17α-epiestriol, and 16β,17α-epiestriol are isomers of estriol that are endogenous weak estrogens. ^[29] Mytatrienediol (16α-methyl-16β-epiestriol 3-methyl ether) is a synthetic derivative of 16β-epiestriol that was never marketed. ^[29] Estriol acetate benzoate, estriol succinate, and estriol tripropionate are synthetic estriol esters that have been marketed for medical use, whereas estriol dihexanoate, estriol dipropionate, and estriol triacetate have not been introduced. ^{[29] [2]} Quinestradol is the 3-cyclopentyl ether of estriol and has also been marketed. ^{[29] [2]} Polyestriol phosphate, an ester of estriol in the form of a polymer, has been marketed previously as well. ^{[98] [100] [51] [101]} These esters, ethers, and polymers are prodrugs of estriol. ^[4] Ethinylestriol and nilestriol are synthetic C17α ethynylated derivatives of estriol. ^{[29] [2]} Ethinylestriol has not been marketed, but nilestriol, which is the 3-cyclopentyl ether of ethinylestriol and a prodrug of it, has been. ^{[29] [2]}

Estetrol (E4), also known as 15α-hydroxyestriol, is a naturally occurring analogue of estriol with an additional hydroxyl group, at the C15α position. ^{[102] [103]} It is closely related to estriol and has similar but non-identical pharmacological properties. ^{[102] [103]} Like estriol, estetrol is a relatively weak and atypical estrogen. ^{[102] [103]} Estetrol is under development for potential clinical use for a variety of indications, such as menopausal hormone therapy and hormonal birth control. ^{[104] [105]}

History

See also: Estriol § History

Estriol was discovered in 1930. ^{[22] [23]} Subsequently, it was introduced for medical use in oral and transdermal formulations under brand names such as Estriol, Oestrosalve, Theelol, and Tridestrin. ^{[106] [107] [108] [25] [109] [110] [24]} In addition, conjugated estriol, containing mainly estriol glucuronide, was marketed in the 1930s, under the brand names Emmenin and Progynon. ^{[106] [108] [25] [109] [111] [112]} They were the first orally active estrogen preparations to be introduced in medicine. ^{[111] [112]} In contrast to estrone, free estriol was never introduced for use by intramuscular injection. ^[113] Estriol continues to be used medically today, widely throughout the world and in a variety of different formulations and brand names. ^{[2] [3] [6]}

Society and culture

Generic names

Estriol is the generic name of estriol in American English and its INN Tooltip International Nonproprietary Name, USP Tooltip United States Pharmacopeia, BAN Tooltip British Approved Name, DCF Tooltip Dénomination Commune Française, and JAN Tooltip Japanese Accepted Name. ^{[29] [2] [114] [3]} It is pronounced /ˌɛstraɪoʊl/ ESS-TREE-ohl. ^[1] Estriolo is the name of estriol in Italian ^[3] and estriolum is its name in Latin, whereas its name remains unchanged as estriol in Spanish, Portuguese, French, and German. ^{[3] [2]} Oestriol, in which the "O" is silent, was the former BAN Tooltip British Approved Name of estriol and its name in British English, ^{[29] [114] [2]} but the spelling was eventually changed to estriol. ^[3]

Brand names

Estriol is or has been marketed under a variety of brand names throughout the world, including Aacifemine, Colpogyn, Elinol, Estriel, Estriol, Estriosalbe, Estrokad, Evalon, Gydrelle, Gynäsan, Gynest, Gynoflor (in combination with lactobacilli), Incurin (veterinary), Klimax-E, OeKolp, Oestro-Gynaedron, Orgestriol, Ortho-Gynest, Ovesterin, Ovestin, Ovestinon, Ovestrion, Ovo-Vinces, Pausanol, Physiogine, Sinapause, Synapause, Synapause-E, Trophicrème, Vago-Med, Vacidox, and Xapro. ^{[2] [3]}

Estriol succinate has been marketed under the brand names Blissel, Evalon, Gelistrol, Hemostyptanon, Orgastyptin, Ovestin, Pausan, Sinapause, Styptanon, Synapsa, Synapasa, Synapausa, and Synapause. ^{[29] [2] [3]} Estriol diacetate benzoate has been marketed under the brand name Holin-Depot and estriol tripropionate has been marketed under the brand name Estriel. ^[29] Polyestriol phosphate has been marketed under the brand names Gynäsan, Klimadurin, and Triodurin. ^{[100] [115] [116]} Emmenin and Progynon were estriol products marketed in the 1930s which were manufactured from the urine of pregnant women and contained estriol conjugates, primarily estriol glucuronide. ^{[111] [112]}

Estriol for multiple sclerosis had the tentative brand name Trimesta but did not complete development and was never marketed. ^[117]

Availability

Estriol is marketed widely throughout the world, including in Europe, South Africa, Australia, New Zealand, Asia, Latin America, and elsewhere. ^{[2] [3]} The medication is also available in some countries in the form of estriol succinate, an ester prodrug of estriol. ^{[2] [29] [118]} Estriol and its esters are not approved for use in the United States or Canada, although estriol has been produced and sold by compounding pharmacies in North America for use as a component of bioidentical hormone therapy. ^{[36] [119]} In addition, topical creams containing estriol are not regulated in the United States and are available over-the-counter in this country. ^[28]

Research

Estriol may have immunomodulatory effects and has been of investigational interest in the treatment of multiple sclerosis and a number of other conditions. ^[18] Estriol succinate was under development for the treatment of multiple sclerosis in the United States and worldwide, and reached phase II clinical trials for this indication, but development was discontinued due to insufficient effectiveness. ^[117] It had the tentative brand name Trimesta. ^[117]

Veterinary use

Estriol is used in veterinary medicine, under the brand name Incurin, in the treatment of urinary incontinence due to estrogen deficiency in dogs. ^{[14] [15] [16] [17]} Certain estrogens, like estradiol, can cause bone marrow suppression in dogs, which can be fatal, but estriol appears to pose less or possibly no risk. ^{[17] [120]}

References

1. Estriol. Dictionary.com.
2. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 407–. ISBN   978-3-88763-075-1.
3. "Estriol". Archived from the original on 2018-07-05. Retrieved 2018-05-20.
4. Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID   16112947. S2CID   24616324.
5. Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 265, 273. ISBN   978-3-642-60107-1.
6. Taylor M (December 2001). "Unconventional estrogens: estriol, biest, and triest". Clin Obstet Gynecol. 44 (4): 864–79. doi:10.1097/00003081-200112000-00024. PMID   11600867. S2CID   27098486.
7. Musey PI, Kirdani RY, Bhanalaph T, Sandberg AA (December 1973). "Estriol metabolism in the baboon: analysis of urinary and biliary metabolites". Steroids. 22 (6): 795–817. doi:10.1016/0039-128X(73)90054-8. PMID   4203562.
8. Dörwald FZ (4 February 2013). "Steroids". Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds. John Wiley & Sons. pp. 486–. ISBN   978-3-527-64565-7.
9. Wentz AC (January 1988). Gynecologic Endocrinology and Infertility for the House Officer. Williams & Wilkins. ISBN   978-0-683-08931-8. Estriol is considered a short-acting estrogen with a half-life of 5 hours.
10. Visser M, Holinka CF, Coelingh Bennink HJ (2008). "First human exposure to exogenous single-dose oral estetrol in early postmenopausal women". Climacteric. 11 (Suppl 1): 31–40. doi:10.1080/13697130802056511. PMID   18464021. S2CID   23568599.
11. Applied Biochemistry of Clinical Disorders (2nd ed.). University of California. 1986. ISBN   978-0-397-50768-9. Because its half-life is about 20 minutes, unconjugated estriol rapidly reflects changes in estriol production.
12. Rueda C, Osorio AM, Avellaneda AC, Pinzón CE, Restrepo OI (August 2017). "The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review". Climacteric. 20 (4): 321–330. doi:10.1080/13697137.2017.1329291. PMID   28622049. S2CID   407950.
13. Zutshi V, Rathore AM, Sharma K (1 January 2005). Hormones in Obstetrics and Gynaecology. Jaypee Brothers Publishers. pp. 101–. ISBN   978-81-8061-427-9.
14. Ettinger SJ, Feldman EC, Cote E (11 January 2017). Textbook of Veterinary Internal Medicine - eBook. Elsevier Health Sciences. pp. 6017, 6380. ISBN   978-0-323-31239-4.
15. Boothe DM (25 July 2011). Small Animal Clinical Pharmacology and Therapeutics - E-Book. Elsevier Health Sciences. pp. 2350–2351. ISBN   978-1-4377-2357-1.
16. Bonagura JD, Twedt DC (10 July 2008). Kirk's Current Veterinary Therapy XIV - E-Book. Elsevier Health Sciences. pp. 772, 4442. ISBN   978-1-4377-1152-3.
17. Papich MG (1 October 2015). Saunders Handbook of Veterinary Drugs: Small and Large Animal. Elsevier Health Sciences. pp. 304–. ISBN   978-0-323-24485-5.
18. Ali ES, Mangold C, Peiris AN (September 2017). "Estriol: emerging clinical benefits". Menopause. 24 (9): 1081–1085. doi:10.1097/GME.0000000000000855. PMID   28375935. S2CID   41137736.
19. Carr BC (2001). "The maternal-fetal-placental unit.". In Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 932, 989, 1061. ISBN   978-0-7817-1750-2.
20. Clark JH, Markaverich BM (1983). "The agonistic and antagonistic effects of short acting estrogens: a review". Pharmacol. Ther. 21 (3): 429–53. doi:10.1016/0163-7258(83)90063-3. PMID   6356176.
21. Clark JH, Markaverich BM (April 1984). "The agonistic and antagonistic actions of estriol". J. Steroid Biochem. 20 (4B): 1005–13. doi:10.1016/0022-4731(84)90011-6. PMID   6202959.
22. Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 31–. ISBN   978-1-4613-2157-6.
23. Sartorelli AC, Johns DG (27 November 2013). Antineoplastic and Immunosuppressive Agents. Springer Science & Business Media. pp. 104–. ISBN   978-3-642-65806-8.
24. Merrill RC (July 1958). "Estriol: a review". Physiological Reviews. 38 (3): 463–480. doi:10.1152/physrev.1958.38.3.463. PMID   13567043.
25. Fluhmann CF (November 1938). "Estrogenic Hormones: Their Clinical Usage". California and Western Medicine. 49 (5): 362–366. PMC   1659459 . PMID   18744783.
26. Vooijs GP, Geurts TB (September 1995). "Review of the endometrial safety during intravaginal treatment with estriol". Eur. J. Obstet. Gynecol. Reprod. Biol. 62 (1): 101–6. doi:10.1016/0301-2115(95)02170-c. hdl: 2066/21059 . PMID   7493689.
27. "Estriol/Lactobacillus - Acerus Pharmaceuticals/Medinova -". AdisInsight. Springer Nature Switzerland AG.
28. Cirigliano M (June 2007). "Bioidentical hormone therapy: a review of the evidence". J Womens Health (Larchmt). 16 (5): 600–31. doi:10.1089/jwh.2006.0311. PMID   17627398.
29. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 899–. ISBN   978-1-4757-2085-3.
30. Mazer C, Israel SL, Charny CW (1946). Diagnosis and treatment of menstrual disorders and sterility. Hoeber. p. 525. 8. PREPARATIONS OF ESTRIOL. Estriol is the least active of all commercially available natural estrogenic substances. A milligram of estriol yields approximately 350 Allen-Doisy rat units. Estriol (Abbott). Capsules containing 0.06, 0.12, and 0.24 mg. Estriol (Lilly). Puvules containing 0.06, 0.12, and 0.24 mg. Theelol (Parke-Davis). Capsules containing 0.06, 0.12, and 0.24 mg.
31. Barr DP (1940). Modern Medical Therapy in General Practice. William & Wilkins Company. p. 194. ISBN   978-0-598-66833-2. Estriol. Estriol (theelol) is trihydroxyestrin. It is a crystalline estrogenic steroid obtained from the urine of pregnant women. It is less actively estrogenic than estrone. Several pharmaceutical houses supply capsules containing 0.06 or 0.12 mg. These may be obtained as Theelol (Parke-Davis), Estriol (Abbott), and Estriol (Lilly).
32. Sollmann TH (1948). A manual of pharmacology and its applications to therapeutics and toxicology. W. B. Saunders. Estriol (Theelol), N.N.R.; characters and solubility as for estrone; considerably less potent. Marketed as capsules of 0.06, 0.12 and 0.24 mg. Dose, 0.06 to 0.12 mg. once to four times daily.
33. Council on Drugs (American Medical Association) (1950). New and Nonofficial Drugs. Lippincott. p. 322. Abbott Laboratories Capsules Estriol: 0.12 mg. and 0.24 mg. Eli Lilly and Company Pulvules Estriol: 0.06 mg., 0.12 mg. and 0.24 mg. Parke, Davis & Company Kapseals Theelol: 0.24 mg.
34. New York State Journal of Medicine. Medical Society of the State of New York. 1939. p. 1760.
35. Lauritzen C (1988). "Natürliche und Synthetische Sexualhormone – Biologische Grundlagen und Behandlungsprinzipien" [Natural and Synthetic Sexual Hormones – Biological Basis and Medical Treatment Principles]. In Schneider HP, Lauritzen C, Nieschlag E (eds.). Grundlagen und Klinik der Menschlichen Fortpflanzung [Foundations and Clinic of Human Reproduction] (in German). Walter de Gruyter. pp. 229–306. ISBN   978-3-11-010968-9. OCLC   35483492.
36. Fugh-Berman A, Bythrow J (July 2007). "Bioidentical hormones for menopausal hormone therapy: variation on a theme". J Gen Intern Med. 22 (7): 1030–4. doi:10.1007/s11606-007-0141-4. PMC   2219716 . PMID   17549577.
37. Greenblatt RB, Natrajan PK, Aksu MF, Tzingounis VA (January 1980). "The fate of a large bolus of exogenous estrogen administered to postmenopausal women". Maturitas. 2 (1): 29–35. doi:10.1016/0378-5122(80)90057-2. PMID   6250009.
38. Adlercreutz H, Martin F, Wahlroos O, Soini E (1975). "Mass spectrometric and mass fragmentographic determination of natural and synthetic steroids in biological fluids". J. Steroid Biochem. 6 (3–4): 247–59. doi:10.1016/0022-4731(75)90140-5. PMID   1186230.
39. Pocket Books (2005). The PDR Pocket Guide to Prescription Drugs. Simon and Schuster. pp. 1540–. ISBN   978-1-4165-1085-7.
40. Bratman S (2003). Mosby's Handbook of Herbs and Supplements and Their Therapeutic Uses . Mosby/Healthgate. ISBN   978-0-323-02015-2.
41. Jaouen G, Top S, McGlinchey MJ (20 April 2015). "The Biological Target Potential of Organometallic Steroids". In Jaouen G, Salmain M (eds.). Bioorganometallic Chemistry: Applications in Drug Discovery, Biocatalysis, and Imaging. John Wiley & Sons. pp. 45–. ISBN   978-3-527-33527-5.
42. Escande A, Pillon A, Servant N, Cravedi JP, Larrea F, Muhn P, et al. (May 2006). "Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta". Biochemical Pharmacology. 71 (10): 1459–1469. doi:10.1016/j.bcp.2006.02.002. PMID   16554039.
43. Prossnitz ER, Arterburn JB (July 2015). "International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators". Pharmacological Reviews. 67 (3): 505–540. doi:10.1124/pr.114.009712. PMC   4485017 . PMID   26023144.
44. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M (May 2010). "Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells". Molecular and Cellular Endocrinology. 320 (1–2): 162–170. doi:10.1016/j.mce.2010.02.006. PMID   20138962. S2CID   24525995.
45. Girgert R, Emons G, Gründker C (December 2014). "Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol". BMC Cancer. 14 (1): 935. doi: 10.1186/1471-2407-14-935 . PMC   4364648 . PMID   25496649.
46. Raynaud JP, Ojasoo T, Bouton MM (1979). "Receptor Binding as a Tool in the Development of New Bioactive Steroids". Drug Design. Medicinal Chemistry: A Series of Monographs. 11: 169–214. doi:10.1016/B978-0-12-060308-4.50010-X. ISBN   978-0-12-060308-4.
47. Ojasoo T, Raynaud JP (November 1978). "Unique steroid congeners for receptor studies". Cancer Research. 38 (11 Pt 2): 4186–4198. PMID   359134.
48. Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen receptors". Journal of Steroid Biochemistry. 27 (1–3): 255–269. doi:10.1016/0022-4731(87)90317-7. PMID   3695484.
49. Raynaud JP, Bouton MM, Moguilewsky M, Ojasoo T, Philibert D, Beck G, et al. (January 1980). "Steroid hormone receptors and pharmacology". Journal of Steroid Biochemistry. 12: 143–157. doi:10.1016/0022-4731(80)90264-2. PMID   7421203.
50. Dunn JF, Nisula BC, Rodbard D (July 1981). "Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma". The Journal of Clinical Endocrinology and Metabolism. 53 (1): 58–68. doi:10.1210/jcem-53-1-58. PMID   7195404.
51. Labhart A (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 548, 551. ISBN   978-3-642-96158-8. The polymer of estradiol or estriol and phosphoric acid has an excellent depot action when given intramuscularly (polyestriol phosphate or polyestradiol phosphate) (Table 16). Phosphoric acid combines with the estrogen molecule at C3 and C17 to form a macromolecule. The compound is stored in the liver and spleen where the estrogen is steadily released by splitting off of the phosphate portion due to the action of alkaline phosphatase. [...] Conjugated estrogens and polyestriol and estradiol phosphate can also be given intravenously in an aqueous solution. Intravenous administration of ovarian hormones offers no advantages, however, and therefore has no practical significance. [...] The following duarations of action have been obtained with a single administration (WlED, 1954; LAURITZEN, 1968): [...] 50 mg polyestradiol phosphate ~ 1 month; 50 mg polyestriol phosphate ~ 1 month; 80 mg polyestriol phosphate ~ 2 months.
52. Kuhl H (September 1990). "Pharmacokinetics of oestrogens and progestogens". Maturitas. 12 (3): 171–97. doi:10.1016/0378-5122(90)90003-O. PMID   2170822.
53. Nelson WO (1936). "Endocrine Control of the Mammary Gland". Physiological Reviews. 16 (3): 488–526. doi:10.1152/physrev.1936.16.3.488. ISSN   0031-9333.
54. Martinez-Manautou J, Rudel HW (1966). "Antiovulatory Activity of Several Synthetic and Natural Estrogens". In Greenblatt RB (ed.). Ovulation: Stimulation, Suppression, and Detection. Lippincott. pp. 243–253. ISBN   978-0-397-59010-0.
55. Herr F, Revesz C, Manson AJ, Jewell JB (1970). "Biological Properties of Estrogen Sulfates". In Bernstein S, Solomon S (eds.). Chemical and Biological Aspects of Steroid Conjugation. Springer. pp. 368–408. doi:10.1007/978-3-642-95177-0. ISBN   978-3-642-49506-9.
56. Clark JH, Peck EJ (1979). "Control of Steroid Receptor Levels and Steroid Antagonism". Female Sex Steroids: Receptors and Function. Monographs on Endocrinology. Vol. 14. Springer. pp. 99–134. doi:10.1007/978-3-642-81339-9_6. ISBN   978-3-642-81341-2. ISSN   0077-1015. PMID   390365.
57. Clark JH, Paszko Z, Peck EJ (January 1977). "Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol". Endocrinology. 100 (1): 91–6. doi:10.1210/endo-100-1-91. PMID   830547.
58. Rabe T, Runnebaum B, Kellermeier-Wittlinger S (17 April 2013). "Hormontherapie". In Runnebaum B, Rabe T (eds.). Gynäkologische Endokrinologie und Fortpflanzungsmedizin: Band 1: Gynäkologische Endokrinologie. Springer-Verlag. pp. 88–. ISBN   978-3-662-07635-4.
59. Kopera H (1991). "Hormone der Gonaden". Hormonelle Therapie für die Frau. Kliniktaschenbücher. Springer. pp. 59–124. doi:10.1007/978-3-642-95670-6_6. ISBN   978-3-540-54554-5. ISSN   0172-777X.
60. Hellberg D, Nilsson S (April 1984). "Comparison of a triphasic oestradiol/norethisterone acetate preparation with and without an oestriol component in the treatment of climacteric complaints". Maturitas. 5 (4): 233–43. doi:10.1016/0378-5122(84)90016-1. PMID   6429481.
61. Lauritzen C (September 1990). "Clinical use of oestrogens and progestogens". Maturitas. 12 (3): 199–214. doi:10.1016/0378-5122(90)90004-P. PMID   2215269.
62. Lauritzen C (June 1977). "[Estrogen thearpy in practice. 3. Estrogen preparations and combination preparations]" [Estrogen therapy in practice. 3. Estrogen preparations and combination preparations]. Fortschritte Der Medizin (in German). 95 (21): 1388–92. PMID   559617.
63. Wolf AS, Schneider HP (12 March 2013). Östrogene in Diagnostik und Therapie. Springer-Verlag. pp. 78–. ISBN   978-3-642-75101-1.
64. Göretzlehner G, Lauritzen C, Römer T, Rossmanith W (1 January 2012). Praktische Hormontherapie in der Gynäkologie. Walter de Gruyter. pp. 44–. ISBN   978-3-11-024568-4.
65. Knörr K, Beller FK, Lauritzen C (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 212–213. ISBN   978-3-662-00942-0.
66. Horský J, Presl J (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". In Horsky J, Presl J (eds.). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN   978-94-009-8195-9.
67. Pschyrembel W (1968). Praktische Gynäkologie: für Studierende und Ärzte. Walter de Gruyter. pp. 598–599. ISBN   978-3-11-150424-7.
68. Lauritzen CH (January 1976). "The female climacteric syndrome: significance, problems, treatment". Acta Obstetricia Et Gynecologica Scandinavica. Supplement. 51: 47–61. doi:10.3109/00016347509156433. PMID   779393.
69. Lauritzen C (1975). "The Female Climacteric Syndrome: Significance, Problems, Treatment". Acta Obstetricia et Gynecologica Scandinavica. 54 (s51): 48–61. doi:10.3109/00016347509156433. ISSN   0001-6349.
70. Kopera H (1991). "Hormone der Gonaden". Hormonelle Therapie für die Frau. Kliniktaschenbücher. pp. 59–124. doi:10.1007/978-3-642-95670-6_6. ISBN   978-3-540-54554-5. ISSN   0172-777X.
71. Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 (Suppl 7): 1929–1936. doi:10.1002/cncr.1980.45.s7.1929. PMID   29603164.
72. Leinung MC, Feustel PJ, Joseph J (2018). "Hormonal Treatment of Transgender Women with Oral Estradiol". Transgender Health. 3 (1): 74–81. doi:10.1089/trgh.2017.0035. PMC   5944393 . PMID   29756046.
73. Ryden AB (1950). "Natural and synthetic oestrogenic substances; their relative effectiveness when administered orally". Acta Endocrinologica. 4 (2): 121–39. doi:10.1530/acta.0.0040121. PMID   15432047.
74. Ryden AB (1951). "The effectiveness of natural and synthetic oestrogenic substances in women". Acta Endocrinologica. 8 (2): 175–91. doi:10.1530/acta.0.0080175. PMID   14902290.
75. Kottmeier HL (1947). "Ueber blutungen in der menopause: Speziell der klinischen bedeutung eines endometriums mit zeichen hormonaler beeinflussung: Part I". Acta Obstetricia et Gynecologica Scandinavica. 27 (s6): 1–121. doi:10.3109/00016344709154486. ISSN   0001-6349. There is no doubt that the conversion of the endometrium with injections of both synthetic and native estrogenic hormone preparations succeeds, but the opinion whether native, orally administered preparations can produce a proliferation mucosa changes with different authors. PEDERSEN-BJERGAARD (1939) was able to show that 90% of the folliculin taken up in the blood of the vena portae is inactivated in the liver. Neither KAUFMANN (1933, 1935), RAUSCHER (1939, 1942) nor HERRNBERGER (1941) succeeded in bringing a castration endometrium into proliferation using large doses of orally administered preparations of estrone or estradiol. Other results are reported by NEUSTAEDTER (1939), LAUTERWEIN (1940) and FERIN (1941); they succeeded in converting an atrophic castration endometrium into an unambiguous proliferation mucosa with 120–300 oestradiol or with 380 oestrone.
76. Rietbrock N, Staib AH, Loew D (11 March 2013). Klinische Pharmakologie: Arzneitherapie. Springer-Verlag. pp. 426–. ISBN   978-3-642-57636-2.
77. Martinez-Manautou J, Rudel HW (1966). "Antiovulatory Activity of Several Synthetic and Natural Estrogens". In Robert Benjamin Greenblatt (ed.). Ovulation: Stimulation, Suppression, and Detection. Lippincott. pp. 243–253.
78. Herr F, Revesz C, Manson AJ, Jewell JB (1970). "Biological Properties of Estrogen Sulfates". Chemical and Biological Aspects of Steroid Conjugation. pp. 368–408. doi:10.1007/978-3-642-49793-3_8. ISBN   978-3-642-49506-9.
79. Duncan CJ, Kistner RW, Mansell H (October 1956). "Suppression of ovulation by trip-anisyl chloroethylene (TACE)". Obstetrics and Gynecology. 8 (4): 399–407. PMID   13370006.
80. Clark JH, Paszko Z, Peck EJ (January 1977). "Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol". Endocrinology. 100 (1): 91–96. doi:10.1210/endo-100-1-91. PMID   830547.
81. Clark JH, Hardin JW, McCormack SA (1979). "Mechanism of action of estrogen agonists and antagonists". Journal of Animal Science. 49 Suppl 2: 46–65. doi:10.1093/ansci/49.supplement_ii.46. PMID   400777.
82. Lunan CB, Klopper A (September 1975). "Antioestrogens. A review". Clinical Endocrinology. 4 (5): 551–572. doi:10.1111/j.1365-2265.1975.tb01568.x. PMID   170029. S2CID   9628572.
83. Rabe T, Runnebaum B, Kellermeier-Wittlinger S (1994). "Hormontherapie" [Hormone Therapy]. In Runnebaum B, Rabe T (eds.). Gynäkologische Endokrinologie und Fortpflanzungsmedizin: Band 1: Gynäkologische Endokrinologie [Gynecological Endocrinology and Reproductive Medicine: Volume 1: Gynecological Endocrinology]. pp. 63–147. doi:10.1007/978-3-662-07635-4_3. ISBN   978-3-662-07635-4.
84. Clark JH, Markaverich BM (1983). "The agonistic and antagonistic effects of short acting estrogens: a review". Pharmacology & Therapeutics. 21 (3): 429–453. doi:10.1016/0163-7258(83)90063-3. PMID   6356176.
85. Clark JH, Markaverich BM (April 1984). "The agonistic and antagonistic actions of estriol". Journal of Steroid Biochemistry. 20 (4B): 1005–1013. doi:10.1016/0022-4731(84)90011-6. PMID   6202959.
86. Terenius L, Ljungkvist I (1972). "Aspects on the mode of action of antiestrogens and antiprogestogens". Gynecologic Investigation. 3 (1): 96–107. doi:10.1159/000301746. PMID   4347201.
87. Moran DJ, McGarrigle HH, Lachelin GC (January 1994). "Maternal plasma progesterone levels fall after rectal administration of estriol". J. Clin. Endocrinol. Metab. 78 (1): 70–2. doi:10.1210/jcem.78.1.8288717. PMID   8288717.
88. Norman AW, Litwack G (23 October 1997). Hormones . Academic Press. pp.  398–. ISBN   978-0-08-053413-8.
89. Kurjak A, Chervenak FA (25 September 2006). Textbook of Perinatal Medicine, Second Edition. CRC Press. pp. 699–. ISBN   978-1-4398-1469-7.
90. Greene MF, Creasy RK, Resnik R, Iams JD, Lockwood CJ, Moore T (25 November 2008). Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice E-Book. Elsevier Health Sciences. pp. 115–. ISBN   978-1-4377-2135-5.
91. Wiegerinck MA, Poortman J, Donker TH, Thijssen JH (January 1983). "In vivo uptake and subcellular distribution of tritium-labeled estrogens in human endometrium, myometrium, and vagina". J. Clin. Endocrinol. Metab. 56 (1): 76–86. doi: 10.1210/jcem-56-1-76 . PMID   6847874.
92. Buchsbaum HJ (6 December 2012). The Menopause. Springer Science & Business Media. pp. 62–. ISBN   978-1-4612-5525-3.
93. Lorenzo J, Horowitz M, Choi Y, Takayanagi H, Schett G (23 September 2015). Osteoimmunology: Interactions of the Immune and Skeletal Systems. Elsevier Science. pp. 216–. ISBN   978-0-12-800627-6.
94. Anderson JN, Peck EJ, Clark JH (April 1974). "Nuclear receptor-estrogen complex: in vivo and in vitro binding of estradiol and estriol as influenced by serum albumin". J. Steroid Biochem. 5 (2): 103–7. doi:10.1016/0022-4731(74)90114-9. PMID   4366454.
95. van Haaften M, Donker GH, Tas AA, Gramberg LG, Blankenstein MA, Thijssen JH (September 1988). "Identification of 16 alpha-hydroxy-estrone as a metabolite of estriol". Gynecol. Endocrinol. 2 (3): 215–21. doi:10.3109/09513599809029346. PMID   3227988.
96. Thijssen JH, Blankenstein MA (1990). "Uptake and metabolism of estradiol by normal and abnormal breast tissues". Ann. N. Y. Acad. Sci. 586 (1): 252–8. Bibcode:1990NYASA.586..252T. doi:10.1111/j.1749-6632.1990.tb17813.x. PMID   2357005. S2CID   35881837.
97. Brown JB (December 1957). "The relationship between urinary oestrogens and oestrogens produced in the body". The Journal of Endocrinology. 16 (2): 202–212. doi:10.1677/joe.0.0160202. PMID   13491750.
98. Lauritzen C, Velibese S (September 1961). "Clinical investigations of a long-acting oestriol (polyoestriol phosphate)". Acta Endocrinologica. 38 (1): 73–87. doi:10.1530/acta.0.0380073. PMID   13759555.
99. Cole LA, Kramer PR (13 October 2015). Human Physiology, Biochemistry and Basic Medicine. Elsevier Science. pp. 122–. ISBN   978-0-12-803717-1.
100. Bachmann FF (January 1971). "Behandlung klimakterisher Beschwerden mit Polyöstriolphosphat" [Treatment of menopausal complants with polyoestriol-phosphate. Experiences with Gynäsan injections]. Munch Med Wochenschr (in German). 113 (5): 166–9. PMID   5107471.
101. Campbell S (6 December 2012). The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London. Springer Science & Business Media. pp. 395–. ISBN   978-94-011-6165-7. In the Federal Republic of Germany between 10 and 20% of all climacteric women are on estrogen treatment. We have the following oral estrogens for a treatment. (t) Conjugated estrogens, (2) estradiol valerate, (3) ethinyl-estradiol and its cyclopentyl-enol ether, (4) stilbestrol, (5) ethinyl-estradiol-methyltestosterone, (6) estriol and estriol succinate, most of them as coated tablets. Several long acting injectable preparations are available: several esters of combined estradiol-testosterone, one of estradiol-dehydroepiandrosterone enanthate and a prolonged polyestriol phosphate are also available. Lastly, depot injections of estradiol- and stilbestrol-esters are on the market.
102. Coelingh Bennink HJ, Holinka CF, Diczfalusy E (2008). "Estetrol review: profile and potential clinical applications". Climacteric. 11 (Suppl 1): 47–58. doi:10.1080/13697130802073425. PMID   18464023. S2CID   24003341.
103. Visser M, Coelingh Bennink HJ (March 2009). "Clinical applications for estetrol" (PDF). J. Steroid Biochem. Mol. Biol. 114 (1–2): 85–9. doi:10.1016/j.jsbmb.2008.12.013. PMID   19167495. S2CID   32081001.
104. "Estetrol - Mithra Pharmaceuticals/Pantarhei Bioscience". AdisInsight. Springer Nature Switzerland AG.
105. "Drospirenone/Estetrol - Mithra Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
106. Greene RR (1941). "Endocrine Therapy for Gynecologic Disorders". Medical Clinics of North America. 25 (1): 155–168. doi:10.1016/S0025-7125(16)36624-X. ISSN   0025-7125.
107. Johnstone RW (November 1936). "Sex Hormone Therapy in Gynæcology". Edinburgh Medical Journal. 43 (11): 680–695. PMC   5303355 . PMID   29648134.
108. Reilly WA (November 1941). "Estrogens: Their Use in Pediatrics". California and Western Medicine. 55 (5): 237–239. PMC   1634235 . PMID   18746057.
109. Fluhmann CF (1944). "Clinical Use of Extracts from the Ovaries". Journal of the American Medical Association. 125 (1): 1. doi:10.1001/jama.1944.02850190003001. ISSN   0002-9955.
110. Macpherson AI (June 1940). "The Use of Œstrogens in Obstetrics and Gynæcology". Edinburgh Medical Journal. 47 (6): 406–424. PMC   5306594 . PMID   29646930.
111. Rooke T (1 January 2012). The Quest for Cortisone. MSU Press. pp. 54–. ISBN   978-1-60917-326-5.
112. Grant GA, Beall D (22 October 2013). "Studies on estrogen conjugates". In Pincus G (ed.). Recent Progress in Hormone Research: The Proceedings of the Laurentian Hormone Conference. Elsevier Science. pp. 307–. ISBN   978-1-4832-1945-5.
113. Cantor EB (September 1956). "A survey of estrogens". Postgraduate Medicine. 20 (3): 224–231. doi:10.1080/00325481.1956.11691266. PMID   13359169.
114. Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 206, 905. ISBN   978-94-011-4439-1.
115. Negwer M, Scharnow HG (4 October 2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. ISBN   978-3-527-30247-5. 8075-01 (6628-01) 37452-43-0 R Polymeric ester with phosphoric acid S Klimadurin, Polyestriol phosphate, Polyostriolphosphat, Triodurin U Depot-estrogen
116. Martindale W, et al. (Royal Pharmaceutical Society of Great Britain. Dept. of Pharmaceutical Sciences) (1993). The Extra Pharmacopoeia. Pharmaceutical Press. p. 2258. ISBN   978-0-85369-300-0. Polyoestriol Phosphate. [...] ingredient of Klimadurin. [...] Triodurin [...].
117. "Estriol succinate - Synthetic Biologics". AdisInsight. Springer Nature Switzerland AG.
118. Platt D (6 December 2012). Geriatrics 3: Gynecology · Orthopaedics · Anesthesiology · Surgery · Otorhinolaryngology · Ophthalmology · Dermatology. Springer Science & Business Media. pp. 6–. ISBN   978-3-642-68976-5.
119. Files JA, Ko MG, Pruthi S (July 2011). "Bioidentical hormone therapy". Mayo Clin. Proc. 86 (7): 673–80, quiz 680. doi:10.4065/mcp.2010.0714. PMC   3127562 . PMID   21531972.
120. Feldman EC, Nelson RW (1 January 2004). Canine and Feline Endocrinology and Reproduction. Elsevier Health Sciences. pp. 839–. ISBN   0-7216-9315-6.

Further reading

• Merrill RC (1958). "Estriol: a review". Physiol. Rev. 38 (3): 463–80. doi:10.1152/physrev.1958.38.3.463. PMID   13567043.
• Clark JH, Hardin JW, McCormack SA (1979). "Mechanism of action of estrogen agonists and antagonists". J. Anim. Sci. 49 (Suppl 2): 46–65. doi:10.1093/ansci/49.supplement_ii.46. PMID   400777.
• Clark JH, Markaverich BM (1983). "The agonistic and antagonistic effects of short acting estrogens: a review". Pharmacol. Ther. 21 (3): 429–53. doi:10.1016/0163-7258(83)90063-3. PMID   6356176.
• Clark JH, Markaverich BM (April 1984). "The agonistic and antagonistic actions of estriol". J. Steroid Biochem. 20 (4B): 1005–13. doi:10.1016/0022-4731(84)90011-6. PMID   6202959.
• Heimer GM (1987). "Estriol in the postmenopause". Acta Obstet Gynecol Scand Suppl. 139: 2–23. doi:10.3109/00016348709156470. PMID   3475930. S2CID   38712328.
• Esposito G (June 1991). "Estriol: a weak estrogen or a different hormone?". Gynecol. Endocrinol. 5 (2): 131–53. doi:10.3109/09513599109028436. PMID   1927578.
• Vooijs GP, Geurts TB (September 1995). "Review of the endometrial safety during intravaginal treatment with estriol". Eur. J. Obstet. Gynecol. Reprod. Biol. 62 (1): 101–6. doi:10.1016/0301-2115(95)02170-c. hdl: 2066/21059 . PMID   7493689.
• Head KA (1998). "Estriol: safety and efficacy" (PDF). Altern Med Rev. 3 (2): 101–13. PMID   9577246.
• Taylor M (December 2001). "Unconventional estrogens: estriol, biest, and triest". Clin Obstet Gynecol. 44 (4): 864–79. doi:10.1097/00003081-200112000-00024. PMID   11600867. S2CID   27098486.
• Ciszko B, Zdrojewicz Z (July 2006). "Znaczenie endogennego i egzogennego estriolu w praktyce klinicznej" [Compliance endogenous and exogenous estriol in clinical practice]. Ginekol. Pol. (in Polish). 77 (7): 559–65. PMID   17076208.
• Perepanova TS, Khazan PL (2007). "[The role of estriol in therapy of urogenital disorders in postmenopausal women]". Urologiia (in Russian) (3): 102–104, 107. PMID   17722629.
• Holtorf K (January 2009). "The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?". Postgrad Med. 121 (1): 73–85. doi:10.3810/pgm.2009.01.1949. PMID   19179815. S2CID   2060730.
• Unlü C, Donders G (2011). "Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review". J Turk Ger Gynecol Assoc. 12 (4): 239–46. doi:10.5152/jtgga.2011.57. PMC   3939257 . PMID   24592002.
• Ali ES, Mangold C, Peiris AN (September 2017). "Estriol: emerging clinical benefits". Menopause. 24 (9): 1081–1085. doi:10.1097/GME.0000000000000855. PMID   28375935. S2CID   41137736.
• Rueda C, Osorio AM, Avellaneda AC, Pinzón CE, Restrepo OI (August 2017). "The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review". Climacteric. 20 (4): 321–330. doi:10.1080/13697137.2017.1329291. PMID   28622049. S2CID   407950.
• Mueck AO, Ruan X, Prasauskas V, Grob P, Ortmann O (April 2018). "Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review". Climacteric. 21 (2): 140–147. doi: 10.1080/13697137.2017.1421923 . PMID   29381086.
• La Rosa VL, Ciebiera M, Lin LT, Fan S, Butticè S, Sathyapalan T, et al. (June 2019). "Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function". Prz Menopauzalny. 18 (2): 116–122. doi:10.5114/pm.2019.86836. PMC   6719636 . PMID   31488961.